Close Menu

NEW YORK (GenomeWeb) – Genomic Health's stock skyrocketed Monday on the news of a study in the New England Journal of Medicine that finally answered the question of how doctors should interpret and act upon an intermediate result from the firm's Oncotype DX breast cancer risk test.

The company's stock closed up more than 23 percent at $48.84 on the Nasdaq on Monday.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.